Conference Day One
8:25 am Chair’s Opening Remarks
TILs Take the Commercial Stage: Spotlighting Clinical Programs to Emphasize TIL Progression
8:30 am Precision Cell Therapies Targeting Immunogenic Clonal Neoantigens in Lung Cancer
Synopsis
- Celebrating breakthroughs in lung cancer to broaden tumor type applications to progress beyond melanoma
9:00 am TIL Prepare for the Commercial Stage
Synopsis
- Preparing for commercialization with the first single administration cell therapy for solid tumors
- Moving TIL to earlier lines with a large scale confirmatory Phase III trial
- Future outlook: looking beyond approval and expanding the pipeline into additional tumor types and Next Gen TIL trials
9:30 am Accelerating the Development of TIL Therapies
Synopsis
Miltenyi Biotec
10:00 am Morning Refreshment Break & Speed Networking
Engineering Next-Gen TIL Products to Turbocharge Therapy Efficacy
11:00 am Engineering TIL with Regulatable Cytokines to Enhance Efficacy & Reduce Systemic Toxicity
Synopsis
- Genetically engineering TIL with regulatable cytokines to overcome limitations of un-engineered TIL
- Leveraging regulated membrane bound IL-15 to improve TIL expansion, persistence, and phenotype
- Eliminating need for high-dose IL-2 therapy to improve safety profile and expand patient eligibility
11:30 am Arming T Cells to Increase Persistence in the Hostile Tumor Microenvironment (TME)
Synopsis
- Creating cells resistant to immunosuppressive factors secreted in the TME
- Increasing resilience of TIL to equip against oxidative stress in the TME
- Demonstrating edited product is viable, stable and has enhanced durability
12:00 pm Expertise Partner Presentation
Synopsis
Bio Sharing Network
12:30 pm Lunch Break & Networking
1:30 pm Creating Engineered TIL Knock Outs to Increase Potency while Maintaining Safety
Synopsis
- Removing PD-1 to avoid toxicity mediated by systemic anti-PD-1 therapy
- Utilizing efficient engineering methods to guarantee cell viability
- Decreasing cost by removing the need for a combination or co-stimulant
2:00 pm Lessons from TIL Therapy in Melanoma
Synopsis
Talk details TBC
2:30 pm A Genome-Wide CRISPR/Cas9 Screening Platform Identifies GT316 as the Top Double KO Combination for Next-Generation TIL Therapy
Synopsis
- ImmuT Finder®, a genome-wide CRISPR/Cas9 screening platform, identifies multiple novel and/or potent immunoregulatory gene targets in primary T cells
- Function validation of top hits from screening identifies GT316 as the most potent combination in TIL, which eradicates tumor growth and persisted longer in mouse models with lower IL-2 dependency
- Early signals of safety and efficacy of GT316 were observed in a first in human trial as monotherapy in advanced solid tumors
3:00 pm Innovation Partner Presentation
Synopsis
Scale Ready
3:10 pm Afternoon Break & Poster Session
3:45 pm Discussion Panel: Evaluating Use of Engineered TIL Vs Non-Engineered TIL to Outline Opportunities
Synopsis
- Comparing the benefits of both therapies from production, efficacy and ease of treatment in the clinic
- Highlighting the opportunity and niche where each therapy type will succeed to promote side by side development
- Discussing whether therapies will co-exist or outcompete to determine future focus
Expanding TIL Treatment Ability to Battle Tumor Types Beyond Melanoma
4:30 pm Defining TIL Features in Rare Tumors
Synopsis
- Overcoming challenges in expansion from rare, immunologically cold tumors
- Defining features of cytotoxic and metabolic dysfunction in TIL
- Deconvoluting TIL behavior in the tumor microenvironment
5:00 pm Equipping TIL to Migrate & Infiltrate Hard-to-Treat Tumor Types
Synopsis
- Optimizing delivery of TIL product to inaccessible tumors to enhance tumor tissue penetration
- Increasing TIL potency to target tumors with high mutational burden
- Enhancing TIL activity to enhance anti-tumor response